论文部分内容阅读
PharmaciaUpjohn公司生产的芳香酶抑制剂依西美坦(exemestane,Aromasin)已获准在美国上市,用于治疗他莫昔芬无效的绝经后妇女进展型乳腺癌患者,2000年第1季度适时将上市。这是本产品获准的第2个国家,1999年英国第1个准许上市,英国作为欧洲相互认可程序中的参照国之一。预期200
PharmaciaUpjohn’s aromatase inhibitor exemestane (Aromasin) has been approved for public release in the United States for the treatment of patients with advanced breast cancer who have failed tamoxifen in postmenopausal women and will be available in the first quarter of 2000. This is the second country where this product is approved, with the first of its kind allowed to go public in 1999 in the UK as one of the reference countries in the European mutual recognition process. Expected 200